

TRANSLATIONAL BREAST CANCER RESEARCH

A JOURNAL FOCUSING ON TRANSLATIONAL RESEARCH IN BREAST CANCER

2020 ANNUAL REPORT

Editorial Office
tbc@amegroups.com

Outline of the Report

1. General Information
2. Editor-in-Chief
3. Geographic Distribution of Editorial Board Members
4. Number of Published Articles in 2020
5. Type of Articles Published in 2020
6. Geographic Distribution of 2020 Corresponding Authors
7. Top Five Most Read Articles in 2020
8. Cover Image Display
9. Propaganda at International Conference
10. Newsletters Promotion
11. Introduction to the Publisher AME

1. General Information



Translational Breast Cancer Research

- Open-access
- Peer-review
- Quarterly publication
- Formally launched in November 2019

A journal focusing on translational research in breast cancer and containing articles dealing with laboratory investigations as well as clinical studies.

2. Editor-in-Chief




Editor-in-Chief

Prof. Dr. Zefei Jiang, MD
Department of Breast Oncology,
The Fifth Medical Center of
Chinese PLA General Hospital, Beijing, China

Dr. Zefei Jiang: our journey beyond the stars and seas

3. Geographic Distribution of Editorial Board Members




- In 2020, the number of editorial team amounted to 30 with leading domestic and overseas experts joining us, who mainly come from China, the USA, UK, Italy, France, Australia and Japan.

* The data were collected from TBCR website on December 31th, 2020.

A Collage of TBCR Editorial Team Members




4. Number of Published Articles in 2020



As a quarterly publication, TBCR published 3 issues in 2020. Each issue focused on a particular theme, which features a current hot topic in breast cancer research.

* The data were collected from TBCR website on December 31st, 2020.


5. Type of Articles Published in 2020



TBCR published 29 pieces of articles in 2020, among which there are Original Article, Guideline, Case Report, Review Article, Editorial and other types etc.

* The date were collected from TBCR website on December 31th, 2020.

6. Geographic Distribution of 2020 Corresponding Authors



The authors of TBCR come from diverse countries. In 2020, there were **29** corresponding authors coming from **7** different countries in TBCR, most of whom come from China, Japan and Australia.

* The data were collected from TBCR website on December 31th, 2020.

7. Top Five Most Read Articles in 2020

Issue	Title	Corresponding Author	Times
Vol 1 (July 2020)	Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study	Zefei Jiang	795
Vol 1 (July 2020)	Pyrotinib: a new promising targeted agent for human epidermal growth factor receptor 2-positive breast cancer	Matteo Lambertini	326
Vol 1 (July 2020)	Analysis of the treatment patterns and safety of early breast cancer patients during the COVID-19 pandemic	Zefei Jiang	257
Vol 1 (April 2020)	CSCO BC guideline: updates for HER2 positive breast cancer in 2020	Zefei Jiang	192
Vol 1 (April 2020)	Tumor microenvironment and future targets of immunotherapy in breast cancer	Qiang Liu	163

*The data were collected from Google Analytics on December 31th, 2020.

8. Cover Image Display



Vol 1 (October 2020)



Vol 1 (July 2020)



Vol 1 (April 2020)

In TBCR, different cover images are designed to highlight the featured article in each issue. For example, the second picture is about a phoenix which is related to an original research representing a randomized, double-blinded, placebo-controlled, multicenter phase 3 trial in 2020 July Issue.

* The pictures were collected from TBCR website on December 31th, 2020.

9. Propaganda at International Conference



In September 2020, TBCR got more exposure at the **23rd Annual Meeting of Chinese Society of Clinical Oncology (CSCO)**, during which the first meet-and-greet between readers and editorial board members is held so as to deepen the communications among authors and readers, and share the purpose and prospect of launching this journal.

By this chance, TBCR gets closer to more leading experts in the field.

10. Newsletters Promotion



ISSN 2218-6778

TBCR TRANSLATIONAL BREAST CANCER RESEARCH

A JOURNAL FOCUSING ON TRANSLATIONAL RESEARCH IN BREAST CANCER

Editor's Choice

Highlights

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance »
 Christine Campbell, John Mathew, *et al.*
 It remains clinically important to identify ER positive breast cancers likely to respond to tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict response. We also assessed whether data from different sample types [tumor microarrays (TMAs) and core biopsies] or tumor sites could be combined for biomarker studies...
[Read Now](#) | [Download PDF](#)

Multidisciplinary treatment of breast cancer under COVID-19 pandemic »
 Pin Gao, Shiheng Li, *et al.*
 The COVID-19 pandemic broke out and spread across the whole world rapidly in the early 2020. To minimize exposure risk and preserve medical resources, multidisciplinary treatment (MDT) of breast cancer has been adjusted...
[Read Now](#) | [Download PDF](#)

Journal Info
[About TBCR](#)
[Editor-in-Chief](#)
[Editorial Board](#)

SCIE-indexed Journals





ISSN 2218-6778

TBCR TRANSLATIONAL BREAST CANCER RESEARCH

A JOURNAL FOCUSING ON TRANSLATIONAL RESEARCH IN BREAST CANCER

Editor's Choice

Highlights

Neoadjuvant chemotherapy versus surgery as the initial option for T3 breast cancer (>5 cm): real-world evidence from the Chinese Society of Clinical Oncology Breast Cancer database »
 Zhenzhen Liu, Meng Lv, *et al.*
 We selected T3 breast cases diagnosed from 2011 to 2017 in the Chinese Society of Clinical Oncology (CSCO) breast cancer (BC) database. These cases were categorized into two groups: the neoadjuvant chemotherapy (NAC) group and the non-NAC group. Adjusted hazard ratios for known predictors of event-free survival (EFS) using Kaplan-Meier and Cox proportional hazards regression...
[Read Now](#) | [Download PDF](#)

Analysis of the treatment patterns and safety of early breast cancer patients during the COVID-19 pandemic »
 Feng Li, Fengrui Xu, *et al.*
 This was an observational real-world study. A total of 958 EBC patients who were admitted to two groups during the epidemic (Observation group: Q1 in 2020, n=422) and the similar time frame from last year (Control group: Q1 in 2019, n=536). The primary end point of the study was the overall safety of treatments, including the proportion of neutropenia, fever, infection and infection of COVID-19...
[Read Now](#) | [Download PDF](#)

Journal Info
[About TBCR](#)
[Editor-in-Chief](#)
[Editorial Board](#)

SCIE-indexed Journals



Electronic newsletters are sent to numerous experts worldwide to timely disseminate key contents of each issue so that the authors' contributions can be distributed internationally.

11. Introduction to the Publisher AME

Meet our Publisher

AME Publishing Company

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world

- 60+ peer-reviewed journals
 - **13 indexed in SCIE**
 - 18 indexed in PubMed/PMC/MEDLINE

- 200+ Medical Books
 - 80+ Medical Books in English
 - 120+ Medical Books in Chinese
 - 150+ Electronic Editions

